Literature DB >> 26283762

Clinical Reasoning: Worsening neurologic symptoms in a brain tumor patient.

Geraldine Faivre1, Elena Pentsova1, Alexis Demopoulos1, Sophie Taillibert1, Marc Rosenblum1, Antonio Omuro2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26283762      PMCID： PMC4548283          DOI： 10.1212/WNL.0000000000001848

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis.

Authors:  C S Straathof; H G de Bruin; D W Dippel; C J Vecht
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

2.  Magnetic Resonance Spectroscopy for Differentiating Pseudo-Progression from True Progression in GBM on Concurrent Chemoradiotherapy.

Authors:  V Sawlani; R Taylor; K Rowley; R Redfern; J Martin; H Poptani
Journal:  Neuroradiol J       Date:  2012-11-09

3.  Leptomeningeal metastases in the MRI era.

Authors:  J L Clarke; H R Perez; L M Jacks; K S Panageas; L M Deangelis
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

4.  The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis.

Authors:  B K Kleinschmidt-DeMasters; Denise M Damek
Journal:  J Neurooncol       Date:  2009-07-16       Impact factor: 4.130

Review 5.  Glioblastoma and other malignant gliomas: a clinical review.

Authors:  Antonio Omuro; Lisa M DeAngelis
Journal:  JAMA       Date:  2013-11-06       Impact factor: 56.272

6.  Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors.

Authors:  Lakshmi Nayak; Martin Fleisher; Rita Gonzalez-Espinoza; Oscar Lin; Katherine Panageas; Anne Reiner; Chhui-Mei Liu; Lisa M Deangelis; Antonio Omuro
Journal:  Neurology       Date:  2013-04-03       Impact factor: 9.910

7.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

Review 8.  Leptomeningeal spinal metastases from glioblastoma multiforme: treatment and management of an uncommon manifestation of disease.

Authors:  Cort D Lawton; Daniel T Nagasawa; Isaac Yang; Richard G Fessler; Zachary A Smith
Journal:  J Neurosurg Spine       Date:  2012-09-07

9.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.

Authors:  W R Wasserstrom; J P Glass; J B Posner
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860
  9 in total
  2 in total

Review 1.  Leptomeningeal Spread in Glioblastoma: Diagnostic and Therapeutic Challenges.

Authors:  Cristina Birzu; Suzanne Tran; Franck Bielle; Mehdi Touat; Karima Mokhtari; Nadia Younan; Dimitri Psimaras; Khe Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Oncologist       Date:  2020-08-31

2.  Intra-operative cerebrospinal fluid sampling versus post-operative lumbar puncture for detection of leptomeningeal disease in malignant paediatric brain tumours.

Authors:  Sharon Y Y Low; Chen Min Wei; Kenneth T E Chang; Chan Yiong Huak; Ng Lee Ping; Seow Wan Tew; David C Y Low
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.